This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

The researchers found that individual SGLT-2 inhibitors showed similar cardiovascular effectiveness at clinically effective ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, ...